TrialRMD open2020

Long-term safety, immunogenicity and efficacy comparing FKB327 with the adalimumab reference product in patients with active rheumatoid arthritis: data from randomised double-blind and open-label extension studies.

Mark C Genovese et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.